Edition:
United Kingdom

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

3.75EUR
13 Dec 2017
Change (% chg)

€0.06 (+1.76%)
Prev Close
€3.68
Open
€3.71
Day's High
€3.75
Day's Low
€3.69
Volume
57,048
Avg. Vol
120,361
52-wk High
€5.78
52-wk Low
€3.63

Summary

Name Age Since Current Position

Mark Shaffar

61 2016 Non-Executive Independent Chairman of the Board

Jan Groen

57 2010 Chief Executive Officer, Executive Director

Jean-Marc Roelandt

52 Executive Vice President & Chief Financial Officer

Joseph Sollee

49 2017 Executive Vice President, Chief Compliance Officer, General Counsel

Christopher Thibodeau

44 2017 Executive Vice President & U.S. Chief Operations Officer

Rudi Marien

72 2011 Non-Executive Director

Jan Pensaert

45 2014 Non-Executive Director

Ruth Devenyns

51 2011 Non-Executive Independent Director

Walter Narajowski

63 2015 Non-Executive Independent Director

Biographies

Name Description

Mark Shaffar

Mr. Mark Shaffar has served as Non-Executive Independent Chairman of the Board of MDxHealth SA since 2016. He has been a consultant and advisor at Shaffar LLC since May 2014 and he also holds a mandate as an independent director of Biocartis Group NV since June 2015. He has thirty-nine years of experience in the biotechnology sector, having held numerous positions at Abbott Laboratories, including divisional vice-president of acquisition and licensing for twelve years, director of technology acquisition and licensing for seven years, and manager of licensing and acquisitions for five years. Mr. Mark Shaffar holds a master of management with a major in management policy, finance from the Northwestern University Kellogg Graduate School of Management and a bachelor of science in biochemistry from the University of Wisconsin-Madison.

Jan Groen

Dr. Jan Groen has been Chief Executive Officer and Executive Director of MDxHealth SA since April 26, 2010. He has more than 30 years of experience in the clinical diagnostics industry, with a particular focus on emerging technologies, product development and commercialization. Dr. Groen was previously the president of Agendia, Inc. and COO of Agendia B.V., responsible for their United States and European diagnostic operations, respectively. Prior to this, he served as VP of Research & Development at Focus Diagnostics, Inc., a subsidiary of Quest Diagnostics, in California. Dr. Groen has held numerous management and scientific positions at ViroClinics B.V., the Erasmus Medical Center, and Akzo-Nobel. Dr. Jan Groen is a supervisory board member of IBL International B.V. Dr. Groen holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.

Jean-Marc Roelandt

Mr. Jean-Marc Roelandt serves as Executive Vice President & Chief Financial Officer of MDxHealth SA. He holds a master’s degree in Applied Economic Sciences from the University of Ghent, Belgium. He started his professional career as audit manager at Ernst & Young and qualified as a Certified Public Accountant (Instituut van de Bedrijfsrevisoren) in 1996, after which he held various senior positions in several publicly listed Belgian companies. He was Chief Financial Officer of Ubizen NV from April 1999 until he joined BHF Kleinwort Benson (previoulsy known as RHJ International) in January of 2005. At BHF Kleinwort Benson Group, he served as Chief Financial Officer and Managing Director for more than 11 years. In addition to his responsibilites as a member of BHF Kleinwort Benson Group’s executive management, he was also appointed Executive Director and Chief Financial Officer of Kleinwort Benson Bank in London in July 2015. He held those positions until the public take-over of BHF Kleinwort Benson group in 2016.

Joseph Sollee

Mr. Joseph (Joe) Sollee has been Executive Vice President, Chief Compliance Officer, General Counsel of MDxHealth SA since 2017. He was Executive Vice President - Corporate Development and Legal Affairs at the Company from 2010. He has provided legal counsel to MDxHealth since its inception in 2003, and in April 2008 joined the management team. rior to joining the Company, Mr. Sollee served as Special Counsel with the law firm of Kennedy Covington (now K&LGates), where he led the Life Sciences Practice Group. Mr. Sollee has more than 10 years of experience in the biotech industry, and has held senior legal and management positions at Triangle Pharmaceuticals and TherapyEdge. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.

Christopher Thibodeau

Mr. Christopher (Chris) Thibodeau has served as Executive Vice President & U.S. Chief Operations Officer of MDxHealth SA since 2017. He was Executive Vice President of Commercial Operations at the Company from September 28, 2010. Mr. Thibodeau brings over 20 years of commercial leadership experience, principally in the life sciences and cancer diagnostics industry. Prior to joining MDxHealth, Mr. Thibodeau served as Senior Director of Marketing at Agendia Inc., Vice President of Sales and Marketing for Numira Biosciences, National Director of Sales US LABS (an industry leader in cancer diagnostic and genomic testing services); and sales and marketing management roles at Ventana Medical. Mr. Thibodeau holds a BA degree from the East Stroudsburg University in Pennsylvania and studied at the Faculte des Lettres in Nancy, France.

Rudi Marien

Mr. Rudi Marien has served as Non-Executive Director of MDxHealth SA since 2011. He is currently Director of Biocartis S.A. (Swirtzeland). He is also President and CEO of Gengest Bvba and Biovest CommVa. Through his management company, Gengest BVBA, Mr. Marien has board mandates in different stock listed (Quest For Growth, Devgen) and private biotech companies (ActogenixNV, Pharmaneuroboost NV, Oystershell NV). Previously Mr. Marien was founder, reference shareholder and managing director of Barc NV group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceuticals studies. He was also the co-founder, reference shareholder and chairman of the biotech company Innogenetics NV.

Jan Pensaert

Mr. Jan Pensaert has served as Non-Executive Director of MDxHealth SA since 2014. He is the founder and CEO/CIO of Valiance Asset Management Ltd., a specialist investment business with offices in London and Guernsey, formed in 2008. From 2003 to 2007, Mr. Pensaert was CEO of La Fayette Investment Management, a leading fund of hedge funds, where he was responsible for the overall business management of the firm, as well as second member of the investment committee. Prior to La Fayette, Mr. Pensaert was responsible for the European-based investment management and research activities of the Permal Group from 2001 to 2003. Prior to that, he was active at Lazard in Corporate Finance M&A. He holds a BA in Business Economics from the University of Gent, Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille.

Ruth Devenyns

Mrs. Ruth Devenyns served as Non-Executive Independent Director of MDxHealth SA since 2011. She has a Master's Degree in Applied Economics (Ghent University, 1986). She has experience in the biotechnology sector. A former analyst and investment banker, Mme. Devenyns was in charge of the venture capital activities in the sector at KBC Private Equity until end of March 2012. She was involved in several IPO’s, private placements and M&A-transactions and held various directorships including Ablynx, Applied Maths and Pronota. At KBC Private Equity she also managed various investments in agrobiotech and seed companies such as CropDesign and Ceres. In June 2012 she joined Korys, the investment structure of the Colruyt family, and became Independent Director of Euronext-listed Devgen until its acquisition by Syngenta in December 2012. Currently, Mme. Devenyns is Director at Biocartis, representing Korys, and Director of FlandersBio, the biotech sector organisation in Flanders. She is Chairman of the Company's Audit Committee.

Walter Narajowski

Basic Compensation